Jade Biosciences will present preclinical data on JADE101 for IgA nephropathy at the ERA Congress on June 6, 2025.
Quiver AI Summary
Jade Biosciences, Inc. announced that new preclinical data on its investigational anti-APRIL monoclonal antibody, JADE101, will be presented at the 62nd European Renal Association Congress in Vienna from June 4-7, 2025. The presentation, delivered by Erin Filbert, will focus on the antibody's design and its potential in treating IgA nephropathy, a chronic autoimmune kidney disease. JADE101 aims to reduce pathogenic IgA levels and improve kidney function with a dosing schedule of at least eight weeks. Following the congress, Jade will hold a conference call on June 9, 2025, to discuss the findings. The company is also preparing to initiate a first-in-human clinical trial for JADE101 in the latter half of 2025, alongside other preclinical candidates.
Potential Positives
- Jade Biosciences will present new preclinical data on its investigational therapy JADE101 at a significant European medical congress, highlighting its commitment to advancing research in autoimmune diseases.
- The lead candidate, JADE101, aims to address a chronic and serious condition, IgA nephropathy, which has a substantial unmet medical need, potentially positioning Jade favorably within the biotechnology sector.
- The development of JADE101 includes innovative half-life extension technology, which may enhance patient convenience and compliance, a critical factor in chronic disease management.
- Jade's planned first-in-human clinical trial for JADE101 is expected to initiate in the second half of 2025, signaling progress in its pipeline and promising potential clinical advancements.
Potential Negatives
- The press release relies heavily on forward-looking statements, which include warnings about the risks and uncertainties associated with the development of JADE101 and other product candidates, potentially leading to skepticism from investors.
- The announcement of preclinical data may not generate the desired excitement or confidence, as the company has not yet begun human clinical trials, which are crucial for validation.
- The need for effective therapies for IgA nephropathy highlights the urgency of the condition, but it may also raise questions about the company's capability to deliver timely solutions amid ongoing clinical development challenges.
FAQ
What is JADE101 developed for?
JADE101 is developed as an anti-APRIL monoclonal antibody for the treatment of IgA nephropathy (IgAN).
When will the new preclinical data for JADE101 be presented?
The preclinical data for JADE101 will be presented during the ERA Congress from June 4-7, 2025.
Who will present the JADE101 data at the conference?
Erin Filbert, Executive Director, Head of Research and Translational Medicine at Jade Biosciences, will present the data.
How can the public access the conference call about JADE101?
The conference call can be accessed by registering on the “Events and Presentations” page of Jade Biosciences' website.
What makes JADE101 unique in its design?
JADE101 is engineered with half-life extension technology, allowing for dosing at intervals of at least eight weeks.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$JBIO Insider Trading Activity
$JBIO insiders have traded $JBIO stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $JBIO stock by insiders over the last 6 months:
- TOM FROHLICH (Chief Executive Officer) purchased 6,000 shares for an estimated $44,400
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Full Release
SAN FRANCISCO and VANCOUVER, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”) (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced new preclinical data on JADE101, its anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy (IgAN), will be presented in an oral session during the 62nd European Renal Association (ERA) Congress, taking place in Vienna from June 4-7, 2025.
The presentation, titled “Discovery and Characterization of JADE101, an Ultra-High Affinity, Half-Life Extended Anti-APRIL Monoclonal Antibody for the Treatment of IgAN, ” will be delivered during the Focused Oral Session on Glomerular and Tubulo-Interstitial Diseases.
Session details are as follows:
- Session Title: Glomerular and Tubulo-interstitial Diseases
- Presenter: Erin Filbert, Executive Director, Head of Research and Translational Medicine, Jade Biosciences
- Presentation Type: Focused Oral
- Room: Focused Oral Room 2
-
Date and Time:
Friday, June 6, 2025, at 4:30 p.m. CET
Conference Call and Webcast
Jade Biosciences will host a conference call and webcast on Monday, June 9, 2025, at 8:00 a.m. ET to discuss the new JADE101 data presented at the 62nd ERA Congress.
Investors and the general public are invited to listen to the live webcast and may register on the “Events and Presentations” page of the company’s website at JadeBiosciences.com . To join the live conference call, participants must register here . Upon registering, you will receive dial-in details and a unique PIN to access the call. A replay of the webcast will be available on the Jade website shortly after the call concludes.
About JADE101
JADE101 is an investigational anti-APRIL (A Proliferation-Inducing Ligand) monoclonal antibody being developed for the treatment of IgA nephropathy (IgAN), a chronic autoimmune kidney disease characterized by the deposition of pathogenic IgA-containing immune complexes in the kidneys. These deposits can lead to proteinuria, declining kidney function, and potentially end-stage kidney disease requiring dialysis or transplantation. By targeting APRIL, a protein involved in the overproduction of IgA, JADE101 aims to reduce the levels of disease-driving IgA, decrease proteinuria, and preserve kidney function. Engineered with half-life extension technology, JADE101 is designed for dosing at intervals of at least eight weeks, offering the potential for durable clinical activity and improved patient convenience, particularly important for a condition often diagnosed in young adulthood and potentially requiring life-long treatment.
About Jade Biosciences, Inc.
Jade Biosciences is focused on developing best-in-class therapies to address critical unmet needs in autoimmune diseases. Its lead candidate, JADE101, targets the cytokine APRIL for the treatment of immunoglobulin A nephropathy, with initiation of a first-in-human clinical trial expected in the second half of 2025. Jade’s pipeline also includes a second development candidate, JADE201, and an undisclosed antibody discovery program, JADE-003, both currently in preclinical development. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount. For more information, visit JadeBiosciences.com and follow the Company on LinkedIn .
Forward-Looking Statements
Certain statements in this communication, other than purely historical information, may constitute "forward-looking statements" within the meaning of the federal securities laws, including for purposes of the "safe harbor" provisions under the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements relating to Jade’s expectations, hopes, beliefs, intentions or strategies regarding the future of its pipeline and business including, without limitation, Jade’s ability to achieve the expected benefits or opportunities with respect to JADE101, JADE201 and the JADE-003 program, including the expected timelines for JADE101 entering the clinic and the potential of Jade’s product candidates to become best-in-class therapies. The words "opportunity," "potential," "milestones," "pipeline," "can," "goal," "strategy," "target," "anticipate," "achieve," "believe," "contemplate," "continue," "could," "estimate," "expect," "intends," "may," "plan," "possible," "project," "should," "will," "would" and similar expressions (including the negatives of these terms or variations of them) may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Jade will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Jade's control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the risks that the planned trial of JADE101 and any future clinical trials may be delayed or may not demonstrate safety and/or efficacy; and the other risks, uncertainties and factors more fully described in Jade’s most recent filings with the Securities and Exchange Commission (including the definitive proxy statement/prospectus filed on Form S-4, most recently amended on March 24, 2025 and declared effective on March 25, 2025) and the Form 8-K filed on May 14, 2025. Should one or more of these risks or uncertainties materialize, or should any of Jade's assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. You should not place undue reliance on forward-looking statements in this communication, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Jade does not undertake or accept any duty to release publicly any updates or revisions to any forward-looking statements. This communication does not purport to summarize all of the conditions, risks and other attributes of an investment in Jade.
Jade Biosciences Contacts
Media
Priyanka Shah
Email:
[email protected]
Phone: 908-447-6134
Investors
Email:
[email protected]
